Barclays cuts target for Indivior stock to USD 43.00
Published on 10/15/2026 at 22:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTargets and dates shape the view
- Barclays lowered its Indivior target from USD 46.00 to USD 43.00 on August 5, 2026.
- Indivior is scheduled to report results on October 29, 2026.
- Indivior stock costs EUR 29.90 at 10:25 p.m. CEST at Lang & Schwarz on October 15, 2026, down 1.58 percent on Nasdaq versus the prior close of October 14, 2026.
- Indivior carries a P/E ratio of 12.05 and a market capitalization of USD 4.2 billion.
Indivior (ISIN US45579U1097) is trading against a lower analyst target after Barclays cut its objective from USD 46.00 to USD 43.00 on August 5, 2026. MarketBeat reported the change. The USD 43.00 target stood 27.90 percent above the Nasdaq price of USD 33.62 at the October 15, 2026 close. Indivior stock was trading at EUR 29.90 at Lang & Schwarz on October 15, 2026 at 10:25 p.m. CEST, down 1.58 percent on Nasdaq versus the prior close of October 14, 2026.
Results date sets the next checkpoint
Indivior is scheduled to report its next results on October 29, 2026. The date is listed by StockIQAI. That calendar point matters because the current analyst target reflects expectations for a specialty pharmaceutical company focused on substance use disorders and serious mental health conditions.
Price position stays inside the yearly range
The Nasdaq price was last at USD 33.62 on October 15, 2026 at 4:00 p.m. ET. Indivior's 52-week range was USD 23.72 to USD 42.81, placing the price 21.47 percent below the high and 41.72 percent above the low. The company had a market capitalization of USD 4.2 billion and an average trading volume of 2,254,746 shares.
Valuation and peer comparison
Indivior carried a trailing P/E ratio of 12.05 on October 15, 2026. The comparison remains mixed across specialty pharmaceuticals.
Comparison with peers
Indivior (Nasdaq, USD): minus 1.58 percent, P/E 12.05, market capitalization USD 4.2 billion
Viatris (Nasdaq, USD): plus 4.47 percent, P/E minus 50.61, market capitalization USD 20.9 billion
Amneal Pharmaceuticals (Nasdaq, USD): plus 1.85 percent, P/E 39.49, market capitalization USD 6.1 billion
Market view stays data-led
The analyst target and the October 29 reporting date give investors two separate reference points. The target remains above the latest Nasdaq price, while the stock's yearly range places the current level below its October high. The daily move was measured against the Nasdaq prior close rather than against a separate German closing quotation.
At Lang & Schwarz, Indivior stock was trading at EUR 29.90 on October 15, 2026 at 10:25 p.m. CEST, down 1.58 percent on Nasdaq versus the prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Indivior stock.
Indivior stock facts
- Company: Indivior Pharmaceuticals Inc
- ISIN: US45579U1097
- Ticker: INDV
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 10:25 p.m. CEST): EUR 29.90
- Change on Nasdaq versus prior close: minus 1.58 percent
- Market capitalization: USD 4.2 billion (as of October 15, 2026)
- 52-week range: USD 23.72-42.81 (as of October 15, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
